The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism
Abstract
We report the first administration of an orally active aldosterone synthase inhibitor, LCI699, to 14 patients with primary aldosteronism. After a 2-week placebo run-in, patients received oral LCI699 (0.5 mg BID) for 2 weeks, LCI699 (1.0 mg BID) for 2 weeks, and placebo for 1 week. We assessed changes in hormone concentrations, plasma potassium levels, and 24-hour ambulatory systolic blood pressure and safety. The supine plasma aldosterone concentration decreased from 540 pmol/L (95% CI: 394 to 739 pmol/L) to 171 pmol/L (95% CI: 128 to 230 pmol/L) after 0.5 mg of LCI699 (−68%; P <0.0001) and to 133 pmol/L (95% CI: 100 to 177 pmol/L) after 1.0 mg of LCI699 (−75%; P <0.0001). Plasma 11-deoxycorticosterone concentrations increased by 710% after 0.5 mg of LCI699 ( P <0.0001) and by 1427% after 1.0 mg of LCI699 ( P <0.0001). The plasma potassium concentration increased from 3.27±0.31 to 4.03±0.33 mmol/L ( P <0.0001) after only 1 week on 0.5 mg of LCI699. Twenty-four–hour ambulatory systolic blood pressure decreased by −4.1 mm Hg (95% CI: −8.1 to −0.1 mm Hg) after 4 weeks of treatment ( P =0.046). Basal plasma cortisol concentrations remained unchanged, whereas plasma adrenocorticotropic hormone concentrations increased by 35% after 0.5 mg of LCI699 ( P =0.08) and by 113% after 1.0 mg of LCI699 ( P <0.0001), and the plasma cortisol response to an adrenocorticotropic hormone test was blunted. All of the variables except plasma 11-deoxycorticosterone concentration returned to initial levels after the placebo. LCI699 was well tolerated. In conclusion, the administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism. This 4-week treatment corrected the hypokalemia and mildly decreased blood pressure. The effects on the glucocorticoid axis were consistent with a latent inhibition of cortisol synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
Connell, J. M. C., MacKenzie, S. M., Freel, E. M., Fraser, R., & Davies, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0030 · Cited by 182
Cited by
Pathological Ventricular Remodeling: Mechanisms: Part 1 of 2
Burchfield, J. S., Xie, M., & Hill, J. A. (2013) · Circulation · doi:10.1161/circulationaha.113.001878 · Cited by 766
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis
Brown, N. J. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.110 · Cited by 451
The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling
Pacurari, M., Kafoury, R., Tchounwou, P. B., & Ndebele, K. (2014) · International Journal of Inflammation · doi:10.1155/2014/689360 · Cited by 374
New approaches in the treatment of hypertension
Oparil, S., & Schmieder, R. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.303603 · Cited by 276
Metadata
- Authors
- Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C., & Plouin, P.-F.
- Venue
- Hypertension
- Published
- 2010-11
- Volume
- 56
- Issue
- 5
- Pages
- 831-838
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2148589377
- Cited by
- 202
- References
- 4
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism. https://app.cochat.ai/papers/10.1161/hypertensionaha.110.157271
- The paper
- Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C., & Plouin, P.-F. (2010). Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism. Hypertension. https://doi.org/10.1161/hypertensionaha.110.157271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.